SuzanneShustermanMD

Pediatric Hematology & Oncology • Boston, MA

Assistant Professor of Pediatrics, Dana-Farber Cancer Institute

Join to view full profile

Dr. Shusterman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shusterman's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-4901

Fax+1 617-632-5710
Is this information wrong?

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1997 - 2000
Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1993 - 1996
University of Massachusetts Medical SchoolClass of 1993

Certifications & Licensure

MA State Medical License 2004 - 2024
PA State Medical License 1997 - 2004
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Start of enrollment: 2004 Mar 15
Completed
Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Start of enrollment: 2005 Aug 01
Completed
Phase 2
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Start of enrollment: 2004 Apr 01
Active, not recruiting
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Start of enrollment: 2007 May 03
Completed
Phase 3
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Start of enrollment: 2006 Mar 01
Completed
Phase 1
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
Completed
Phase 2
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Start of enrollment: 2007 Aug 06
Active, not recruiting
Phase 3
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias Start of enrollment: 2006 May 01
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Oct 30
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Start of enrollment: 2007 Mar 01
Completed
Phase 3
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01
Completed
Phase 2
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01
Completed
Phase 2
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment Start of enrollment: 2009 Apr 01
Completed
Phase 1
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2009 Jun 01
Completed
Phase 1
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2009 Jun 01
Terminated
Phase 1
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2009 Dec 21
Completed
Phase 3
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Jun 01
Completed
Phase 1
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09
Completed
Phase 1, Phase 2
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Start of enrollment: 2012 Aug 01
Completed
Phase 2
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2013 Aug 28
Completed
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 2
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1
Roles: Contact
Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01
Recruiting
Roles: Contact
MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study.
Cohn, S. L., Erica C Kaye, Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N Baker, Susan L Cohn, Lisa R Diller, Julia L Glade Bender, M Meaghan Granger, Araz Mara...> ;Cancer. 2024 Apr 1
A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors.
Raja Shaikh, Brent R Weil, Christopher B Weldon, Nan Chen, Wendy B London, Morgan Krush, Megan Anderson, Mark Gebhardt, Alanna J Church, Steven G DuBois, Yana Pikman, ...> ;Cancer Medicine. 2023 Jun 1
9 citations
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macro...
Benjamin J Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D Weiss, Michelle Choe, Jennif...> ;Journal of Clinical Oncology. 2023 Jan 20
6 citations
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Ami V Desai, Mark A Applebaum, Theodore G Karrison, Akosua Oppong, Cindy Yuan, Katherine R Berg, Kyle MacQuarrie, Elizabeth Sokol, Anurekha G Hall, Navin Pinto, Ian Wo...> ;Cancer. 2022 Aug 1
35 citations
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Jane...> ;Neuro-Oncology. 2022 Oct 3
2 citations
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors
Holly J. Meany, Brigitte C. Widemann, Pamela S. Hinds, Rochelle Bagatell, Suzanne Shusterman, Emily Stern, Nalini Jayaprakash, Cody J. Peer, William D. Figg, O Morgan ...> ;Pediatric Blood & Cancer. 2021 Aug 12
25 citations
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report ...
Steven G. DuBois, M. Meaghan Granger, Susan Groshen, Denice D. Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyu...> ;Journal of Clinical Oncology. 2021 Jul 16
6 citations
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology
David S. Shulman, Lulla V Kiwinda, Stacey Edwards, Catherine Clinton, Sarah K. Hunt, Lianne Greenspan, Kristen Lawler, Gregory H. Reaman, Hasan Al-Sayegh, Kira Bona, A...> ;Cancer Medicine. 2021 Mar 9
2 citations
Facial Paralysis From Post-transplant Lymphoproliferative Disorder.
Joonas Toivonen, David S. Shulman, Suzanne Shusterman, Caroline D. Robson, Meredith L. Saillant, Dennis S. Poe> ;Otology & Neurotology. 2021 Jan 13
12 citations
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic sma...
Kevin X. Liu, Natalie B. Collins, Katie A. Greenzang, Elissa Furutani, Kevin Campbell, Andrew Groves, Elizabeth Mullen, Suzanne Shusterman, Jennifer Spidle, Karen J. M...> ;Pediatric Blood & Cancer. 2020 Oct 1
27 citations
Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer.
Jennifer W. Mack, Hajime Uno, Clare J. Twist, Rochelle Bagatell, Abby R. Rosenberg, Araz Marachelian, M. Meaghan Granger, Julia Glade Bender, Justin N. Baker, Julie R....> ;Journal of Pain and Symptom Management. 2020 Oct 1
32 citations
Unrealistic parental expectations for cure in poor‐prognosis childhood cancer
Jennifer W. Mack, Angel M. Cronin, Hajime Uno, Suzanne Shusterman, Clare J. Twist, Rochelle Bagatell, Abby R. Rosenberg, Araz Marachelian, M. Meaghan Granger, Julia Gl...> ;Cancer. 2020 Jan 15
16 citations
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.
Kirsty Hillier, Amy Hughes, Robert C. Shamberger, Suzanne Shusterman, Antonio R. Perez-Atayde, Ari J. Wassner, Anthony J. Iafrate, Adrian M. Dubuc, Katherine A. Janewa...> ;Thyroid. 2019 Nov 1
16 citations
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Suzanne Shusterman, Arlene Naranjo, Collin Van Ryn, Hank Ja, Marguerite T. Parisi, Barry L. Shulkin, Sabah Servaes, Wendy B. London, Hiroyuki Shimada, Jacek Gan, Steve...> ;Clinical Cancer Research. 2019 Oct 15
8 citations
Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma.
Jean-Marc Gauguet, Tamara Pace-Emerson, Frederick D. Grant, Suzanne Shusterman, Steven G. DuBois, A. Lindsay Frazier, Stephan D. Voss> ;Pediatric Blood & Cancer. 2017 Apr 1
18 citations
Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation.
Richard Li, Alexei L. Polishchuk, Steven G. DuBois, Randall A. Hawkins, Stephanie W. Lee, Rochelle Bagatell, Suzanne Shusterman, Christine E. Hill-Kayser, Hasan Al-Say...> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Feb 1
145 citations
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat)...
Marian H. Harris, Steven G. DuBois, Julia L. Glade Bender, AeRang Kim, Brian D. Crompton, Erin Parker, Ian P. Dumont, Andrew L. Hong, Dongjing Guo, Alanna J. Church, K...> ;JAMA Oncology. 2016 May 1
115 citations
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and ...
Deepa K. Krishnadas, Suzanne Shusterman, Fanqi Bai, Lisa Diller, Janice E. Sullivan, Alexandra Cheerva, Rani E. George, Kenneth G. Lucas> ;Cancer Immunology, Immunotherapy. 2015 Jun 24
Neuroblastoma Presenting as Facial Nerve Palsy and Bulging Tympanic Membrane
Miya E. Bernson-Leung, Prasanna Ananth, Suzanne Shusterman> ;Clinical Pediatrics. 2015 Feb 1
21 citations
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Robin E. Norris, Suzanne Shusterman, Lia Gore, Jodi A. Muscal, Margaret E. Macy, Elizabeth Fox, Noah Berkowitz, Aby Buchbinder, Rochelle Bagatell> ;Pediatric Blood & Cancer. 2014 Oct 1
14 citations
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621)
Elizabeth Fox, Yael P. Mosse, Holly M. Meany, James G. Gurney, Geetika Khanna, Hollie A. Jackson, Gary Gordon, Suzanne Shusterman, Julie R. Park, Susan L. Cohn, Peter ...> ;Pediatric Blood & Cancer. 2014 Jun 1
14 citations
Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy
Robert Markelewicz, William A. Lorenzen, Suzanne Shusterman, Frederick D. Grant, Frederic H. Fahey> ;Clinical Nuclear Medicine. 2013 Aug 1
29 citations
Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma
Stephan A. Grupp, Eline T. Luning Prak, Jean D. Boyer, Kenyetta McDonald, Suzanne Shusterman, Edward Thompson, Colleen Callahan, Abbas F. Jawad, Bruce L. Levine, Carl ...> ;Clinical Cancer Research. 2012 Dec 15
27 citations
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
Steven G. DuBois, Suzanne Shusterman, Joel M. Reid, Ashish M. Ingle, Charlotte H. Ahern, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Peter C. Adamson, Susan M. Bl...> ;Cancer Chemotherapy and Pharmacology. 2012 Apr 1
22 citations
Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.
Suzanne Shusterman, Frederick D. Grant, William A. Lorenzen, Royal T. Davis, Stephen Laffin, Laura A. Drubach, Frederic H. Fahey> ;Seminars in Nuclear Medicine. 2011 Sep 1
Join now to see all